Circulating Tumor DNA Reference Standards

AMSBIO announce the launch of a new range of circulating tumor DNA (ctDNA) Reference Standards for cancer disease management research. A critical goal in cancer disease management is early detection. When detected early, cancer progression can be arrested using techniques such as targeted therapy, chemotherapy and surgery thereby increasing the chances of survival and a higher quality of life. Liquid biopsy offers the promise of providing a quick Liquid biopsy offers the promise of providing a quick, non-invasive and cost-effective alternative...

Original Article: Circulating Tumor DNA Reference Standards

More From BioPortfolio on "Circulating Tumor DNA Reference Standards"